Fluorouracil (CAS: 51-21-8)
|
SKU-Pack Size | Availability | Size | Price | |
EBC51162-1ML | In Stock | 1mL(10mM in DMSO) | €76.70 | |
EBC51162-200MG | In Stock | 200mg | €50.70 | |
EBC51162-1G | In Stock | 1g | €63.70 | |
EBC51162-5G | In Stock | 5g | €128.70 |
Please Select The Country You Are In To Find Your Local Distributor. |
Betaclonal | Phone£º+34 (0)91 471 6763 | |
29/1 Lomonosovsky Pr, | E-mail£ºtech@betaclonal.com | |
Spain | Madrid, Spain | Web£ºwww.betaclonal.com |
Product Information | |||||||||||||||||||||
Synonym(s) | 5-FU; 2,4-dioxo-5-fluoropyrimidine; 5-Fluorouracil; Efudex; Adrucil; Carac | ||||||||||||||||||||
Chemical Name | 5-fluoro-1H-pyrimidine-2,4-dione | ||||||||||||||||||||
Application | Fluorouracil is a DNA synthesis blocker which arrests the cell cycle in G2 | ||||||||||||||||||||
CAS Number | 51-21-8 | ||||||||||||||||||||
Purity | ¡Ý98.0% | ||||||||||||||||||||
Molecular Weight | 130.08 | ||||||||||||||||||||
Molecular Formula | C₄H₃FN₂O₂ | ||||||||||||||||||||
SMILES | C1=C(C(=O)NC(=O)N1)F | ||||||||||||||||||||
Target & IC50 | HeLa: IC50 = 1 ¦ÌM L1210 : IC50 = 0.63 ¦ÌM HaCaT : IC50 = 0.4 ¦ÌM PC-3: IC50 = 16 nM |
||||||||||||||||||||
Solubility | DMSO: 100 mg/mL (768.76 mM)
Water: 20 mg/mL (153.75 mM) |
||||||||||||||||||||
Preparing Stock Solutions |
|
||||||||||||||||||||
Shipping | Gel Pack | ||||||||||||||||||||
Storage | Store at 2-8¡ãC | ||||||||||||||||||||
Research Use | For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use. |
Product Description | |
Fluorouracil is a potent antitumor agent that interferes with DNA synthesis via noncompetitive inhibition of thymidylate synthase (TS). The interruption of this enzyme blocks the synthesis of pyrimidine thymidine, a nucleotide required for DNA replication. Fluorouracil Induces apoptosis in human primary and metastatic colon adenocarcinoma cell lines in vitro. It has also been shown to arrest the cell cycle at the G2 phase. Fluorouracil acts as an antimetabolite to uracil. Research in mice has shown that fluorouracil administration may lead to potential degeneration of the CNS by damage to oligodendrocytes responsible for production of myelin sheaths. |
Specific Protocols | |